Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation

Viola, Francesco; Mapelli, Chiara; Carducci, F. Tresca; Vezzola, Diego; Ratiglia, Roberto

doi:10.1038/eye.2010.33

Cited by 4 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, anti-VEGF therapy is the most investigated modality which could be applied alone26,27 or combined with PDT 10,11,28. However, IVR + PDT is likely to be a very expensive therapy and intravitreal bevacizumab + PDT is not possible without off-label use of bevacizumab under current circumstances.…”

Section: Discussionmentioning

confidence: 99%

Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation

Nakano¹,

Honda²,

Oh³

et al. 2012

OPTH

View full text Add to dashboard Cite

BackgroundThe purpose of this work was to compare the efficacy of photodynamic therapy (PDT) with or without posterior subtenon injections of triamcinolone acetonide (STA) or intravitreal injections of ranibizumab (IVR) for retinal angiomatous proliferation (RAP).MethodsThirty-seven eyes from 33 consecutive patients with RAP were treated by PDT monotherapy (Group 1), PDT combined with STA (Group 2), or PDT combined with IVR (Group 3). The best-corrected visual acuity, greatest linear dimension, central retinal thickness, and number of treatments were compared among the three groups.ResultsThe change in mean best-corrected visual acuity (logMAR) at month 3, 6, and 12 after the initial treatment was better in Group 2 (−0.13, −0.23, and −0.21, respectively) and Group 3 (−0.018, 0.0028, and −0.0067, respectively) than in Group 1 (0.13, 0.19, and 0.23, respectively); Group 1 versus Group 2 was statistically significant (P = 0.018). The mean central retinal thickness was reduced from baseline in all groups, but the reduction amplitude was significantly greater in Group 2 than in Group 1 and Group 3. The mean number of treatments was significantly lower in Group 2 (1.1 ± 0.4) and Group 3 (1.5 ± 0.5) than in Group 1 (2.9 ± 0.9) in the 12 months after the initial treatment.ConclusionTreatment with STA + PDT may be an effective therapy for RAP lesions over 12 months of follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation

Nakano¹,

Honda²,

Oh³

et al. 2012

OPTH

View full text Add to dashboard Cite

show abstract

Therapie der retinalen angiomatösen Proliferation im Stadium III

et al. 2012

View full text Add to dashboard Cite

Retinal angiomatous proliferation (RAP) is a subtype of exudative age-related macular degeneration which is characterized by an intraretinal origin of the lesion and a particularly poor prognosis. In this retrospective case study 33 eyes from 33 patients with stage III RAP lesions were included and initially treated with 3 intravitreal injections of 0.5 mg ranibizumab at monthly intervals. Criteria for extended treatment were visual deterioration, fresh bleeding, residual fluid or increase of the central retinal thickness in optical coherence tomography (OCT) as well as persisting activity in fluorescence angiography (FLA). The follow-up period was 8 months. The mean best corrected visual acuity (BCVA) increased insignificantly from logMAR 0.71 at the start of therapy to logMAR 0.67 after the first 3 intravitreal treatment injections and remained stable up to 8 months. The mean decrease of the central retinal thickness after 4 months (-90 µm) and after 8 months (-70 µm) was significant. Of the patients included in the study 67 % were treated repeatedly and the mean frequency of reinjections was 2.27 injections after 8 months. The intravitreal injection of ranibizumab in patients with stage III RAP lesions resulted in functional and anatomical stabilization. In most cases repeated treatment is necessary which underlines the urgent need for close surveillance in follow-up.

show abstract

One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation

et al. 2012

View full text Add to dashboard Cite

show abstract

Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation

Cited by 4 publications

References 28 publications

Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation

Effect of photodynamic therapy (PDT), posterior subtenon injection of triamcinolone acetonide with PDT, and intravitreal injection of ranibizumab with PDT for retinal angiomatous proliferation

Therapie der retinalen angiomatösen Proliferation im Stadium III

One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation

Contact Info

Product

Resources

About